|
Hereditary cancer risk assessment in the community urology practice setting. |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer |
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - pathnostics; United Medical |
|
|
Consulting or Advisory Role - Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |